Citigroup Inc Pliant Therapeutics, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Pliant Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 49,540 shares of PLRX stock, worth $610,332. This represents 0.0% of its overall portfolio holdings.

Number of Shares

49,540

Previous 17,549 182.3%

Holding current value

$610,332

Previous $188,000 195.21%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$10.52 - $14.35 $336,545 - $459,070	31,991 Added 182.3%	49,540 $555,000
Q2 2024 Aug 12, 2024	SELL	$10.58 - $15.61 $2.07 Million - $3.06 Million	-195,756 Reduced 91.77%	17,549 $188,000
Q1 2024 May 10, 2024	BUY	$14.14 - $19.59 $2.01 Million - $2.78 Million	141,830 Added 198.43%	213,305 $3.18 Million
Q4 2023 Feb 09, 2024	BUY	$12.85 - $19.15 $744,644 - $1.11 Million	57,949 Added 428.43%	71,475 $1.29 Million
Q3 2023 Nov 09, 2023	SELL	$14.58 - $20.15 $156,851 - $216,773	-10,758 Reduced 44.3%	13,526 $234,000
Q2 2023 Aug 10, 2023	SELL	$18.12 - $30.56 $9,223 - $15,555	-509 Reduced 2.05%	24,284 $440,000
Q1 2023 May 11, 2023	SELL	$18.73 - $36.26 $13,148 - $25,454	-702 Reduced 2.75%	24,793 $659,000
Q4 2022 Feb 09, 2023	BUY	$17.0 - $25.43 $337,331 - $504,607	19,843 Added 351.08%	25,495 $492,000
Q3 2022 Nov 10, 2022	BUY	$7.67 - $24.23 $34,369 - $108,574	4,481 Added 382.66%	5,652 $118,000
Q2 2022 Aug 10, 2022	SELL	$4.11 - $8.75 $3,662 - $7,796	-891 Reduced 43.21%	1,171 $9,000
Q1 2022 May 12, 2022	SELL	$7.01 - $14.1 $40,118 - $80,694	-5,723 Reduced 73.51%	2,062 $14,000
Q4 2021 Feb 10, 2022	BUY	$12.27 - $18.26 $35,067 - $52,187	2,858 Added 58.01%	7,785 $105,000
Q3 2021 Nov 10, 2021	BUY	$16.48 - $28.98 $81,196 - $142,784	4,927 New	4,927 $83,000

Others Institutions Holding PLRX

# of Institutions

168

Shares Held

63.2M

Call Options Held

245K

Put Options Held

373K

View Full List

About PLIANT THERAPEUTICS, INC.

Ticker PLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,682,000
Market Cap $600M
Description
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a tri...

More about PLRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account